Explore /
Poster
/ Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with <em>EGFR</em>-mutant lung cancers.

Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.

Authors

Adam Jacob Schoenfeld

MSKCC, New York, NY

Adam Jacob Schoenfeld , Joseph Minhow Chan , Hira Rizvi , Natasha Rekhtman , Yahya Daneshbod , Daisuke Kubota , Jason C. Chang , Maria E. Arcila , Marc Ladanyi , Romel Somwar , Mark G. Kris , Dana Pe'er , Gregory J. Riely , Helena Alexandra Yu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9028)

DOI

10.1200/JCO.2019.37.15_suppl.9028

Abstract #

9028

Poster Bd #

351

Abstract Disclosures

Similar Posters

Poster

2015 ASCO Annual Meeting

Migration to next-generation sequencing and the identification of <i>RET</i> and <i>ROS1</i> rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0).

Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0).

First Author: Mark G. Kris

Poster

2023 ASCO Annual Meeting

$A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).$